<DOC>
	<DOCNO>NCT00496197</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness intravenous anidulafungin ( Eraxisâ„¢ ) patient diagnosis candidemia invasive candidiasis , fungus infection blood tissue . Currently drug approve treatment use daily dose IV medication 14 day fungus disappears blood . This study evaluate effectiveness intravenous anidulafungin administer 5-28 day follow oral antifungal medication . Study patient assess response treatment throughout study drug treatment period .</brief_summary>
	<brief_title>Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidemia</mesh_term>
	<mesh_term>Candidiasis , Invasive</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Anidulafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Male female subject &gt; equal 18 year age . Presence candidemia ( positive blood culture ) invasive candidiasis ( histopathologic cytopathologic examination needle aspiration biopsy specimen normally sterile site exclude mucous membrane show yeast cell ) obtain within prior 96 hour screen visit . Subjects receive one prior dose echinocandin polyene . Subjects hypersensitivity anidulafungin , echinocandins azoles . Presence confirm suspect Candida osteomyelitis , endocarditis meningitis . Subjects infect prosthetic device remove within 24 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>candidemia</keyword>
	<keyword>invasive candidiasis</keyword>
	<keyword>fungal bloodstream infection</keyword>
</DOC>